Search

Your search keyword '"Richard P. Schlenk"' showing total 5 results
Start Over Author "Richard P. Schlenk" Publisher wiley
5 results on '"Richard P. Schlenk"'

1. S135: NEXT-GENERATION SEQUENCING-BASED MEASURABLE RESIDUAL DISEASE MONITORING IN ACUTE MYELOID LEUKEMIA WITH FLT3 INTERNAL TANDEM DUPLICATION TREATED WITH INTENSIVE CHEMOTHERAPY PLUS MIDOSTAURIN

Author

Frank G Rücker, Lars Bullinger, Sibylle Cocciardi, Sabrina Skambraks, Tamara J Luck, Daniela Weber, Isabelle Schneider, Andrea Corbacioglu, Verena I Gaidzik, Ekaterina Jahn, Nikolaus Jahn, Silke Kapp-Schwoerer, Anika Schrade, Frauke Theis, Walter Fiedler, Helmut R Salih, Gerald Wulf, Hans Salwender, Thomas Schroeder, Katharina S Götze, Thomas Kindler, Michael Lübbert, Richard F Schlenk, Felicitas Thol, Michael Heuser, Arnold Ganser, Hartmut Döhner, and Konstanze Döhner

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Published
2023
Full Text
View/download PDF

3. P483: QUANTUM-FIRST TRIAL: FLT3-ITD–SPECIFIC MEASURABLE RESIDUAL DISEASE (MRD) CLEARANCE IS ASSOCIATED WITH IMPROVED OVERALL SURVIVAL

Author

Mark J Levis, Harry P. Erba, Pau Montesinos, Radovan Vrhovac, Elżbieta Patkowska, Hee-Je Kim, Pavel Zak, Po-Nan Wang, Jaime E. Connolly Rohrbach, Ken C.N. Chang, James Hanyok, LI Liu, Yasser Mostafa Kamel, Arnaud Lesegretain, Jorge Cortes, Mikkael A. Sekeres, Hervé Dombret, Sergio Amadori, Jianxiang Wang, Richard F. Schlenk, and Alexander E. Perl

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Published
2023
Full Text
View/download PDF

5. Ruxolitinib is effective in the treatment of a patient with refractory T‐ALL

Author

Sonia Jaramillo, Hannah Hennemann, Peter Horak, Veronica Teleanu, Christoph E. Heilig, Barbara Hutter, Albrecht Stenzinger, Hanno Glimm, Benjamin Goeppert, Carsten Müller‐Tidow, Stefan Fröhling, Stefan Schönland, and Richard F. Schlenk

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Abstract

Abstract T‐cell acute lymphoblastic leukemia (T‐ALL) is a rare, aggressive T‐cell malignancy. Chemotherapy alone cures only 25‐45% of the cases, thus, novel treatment agents and strategies are urgently needed. We assessed the efficacy of ruxolitinib in a patient with a cutaneous relapse after allogeneic blood cell transplantation of a refractory T‐ALL with a Janus kinase 3 (JAK3) mutation. In this case report, we were able to show the potential benefit of the JAK inhibitor ruxolitinib in JAK3‐mutated refractory T‐ALL and emphasize the importance of integrating molecular markers in current treatment decision making for patients with T‐ALL.

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results